X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ranibizumab (2976) 2976
humans (2842) 2842
ophthalmology (2543) 2543
male (1937) 1937
female (1914) 1914
intravitreal injections (1776) 1776
aged (1630) 1630
bevacizumab (1586) 1586
macular degeneration (1572) 1572
angiogenesis inhibitors - administration & dosage (1409) 1409
vascular endothelial growth factor a - antagonists & inhibitors (1360) 1360
middle aged (1236) 1236
treatment outcome (1099) 1099
vascular endothelial growth factor (1059) 1059
aged, 80 and over (986) 986
tomography, optical coherence (978) 978
retrospective studies (863) 863
visual acuity (862) 862
follow-up studies (826) 826
angiogenesis inhibitors - therapeutic use (794) 794
fluorescein angiography (786) 786
endothelial growth-factor (755) 755
macular degeneration - drug therapy (710) 710
visual acuity - physiology (623) 623
eye diseases (612) 612
choroidal neovascularization - drug therapy (611) 611
antibodies, monoclonal, humanized (589) 589
diabetic retinopathy (589) 589
ranibizumab - administration & dosage (585) 585
antibodies, monoclonal, humanized - administration & dosage (559) 559
genetic structures (548) 548
prospective studies (542) 542
wet macular degeneration - drug therapy (537) 537
macular edema - drug therapy (526) 526
age-related macular degeneration (511) 511
choroidal neovascularization (483) 483
retina (478) 478
photodynamic therapy (448) 448
care and treatment (442) 442
antibodies, monoclonal - administration & dosage (438) 438
therapy (438) 438
aflibercept (425) 425
injection (409) 409
edema (408) 408
age (401) 401
verteporfin (390) 390
physiological aspects (388) 388
diabetes (385) 385
time factors (378) 378
neovascularization (377) 377
adult (374) 374
diabetic retinopathy - drug therapy (367) 367
antibodies, monoclonal, humanized - therapeutic use (350) 350
patients (350) 350
sense organs (348) 348
angiogenesis inhibitors - adverse effects (335) 335
injections (331) 331
optical coherence tomography (325) 325
analysis (324) 324
drug therapy (313) 313
recombinant fusion proteins - administration & dosage (313) 313
fundus oculi (305) 305
medicine & public health (304) 304
visual acuity - drug effects (298) 298
research (293) 293
receptors, vascular endothelial growth factor - administration & dosage (289) 289
vegf (288) 288
studies (284) 284
abridged index medicus (283) 283
animals (283) 283
eye (281) 281
retinopathy (278) 278
vitreous body (278) 278
safety (274) 274
wet macular degeneration - diagnosis (261) 261
macular edema - etiology (260) 260
intravitreal injection (256) 256
choroidal neovascularization - etiology (255) 255
pharmacology & pharmacy (251) 251
anti-vegf (250) 250
dose-response relationship, drug (249) 249
diabetic macular edema (246) 246
efficacy (244) 244
clinical trials (241) 241
ranibizumab - therapeutic use (241) 241
bevacizumab - administration & dosage (240) 240
medical imaging (240) 240
intravitreal bevacizumab (238) 238
retina - pathology (230) 230
wet macular degeneration - physiopathology (230) 230
antibodies, monoclonal - therapeutic use (227) 227
endothelial growth factors (227) 227
choroidal neovascularization - diagnosis (225) 225
acuity (224) 224
macular edema (224) 224
risk factors (223) 223
avastin (221) 221
angiogenesis (217) 217
prevalence (216) 216
macular degeneration - complications (213) 213
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3406) 3406
German (97) 97
French (49) 49
Spanish (32) 32
Portuguese (20) 20
Russian (17) 17
Japanese (10) 10
Polish (9) 9
Czech (8) 8
Chinese (5) 5
Norwegian (4) 4
Swedish (3) 3
Turkish (3) 3
Danish (2) 2
Dutch (1) 1
Hebrew (1) 1
Hungarian (1) 1
Icelandic (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 2018, Volume 2018, Issue 1, p. CD009734
Background Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti‐VEGF... 
Vascular Endothelial Growth Factor A | Eye Disorders | Intravitreal Injections | Laser Therapy | Combined Modality Therapy | Retinal disease | Angiogenesis Inhibitors | Retinopathy of Prematurity | Retinal diseases | Bevacizumab | Randomized Controlled Trials as Topic | Retinal Detachment | Other retinal diseases | Aptamers, Nucleotide | Neonatal care | Ranibizumab | Child health | Eyes & vision | Other neonatal care | Medicine General & Introductory Medical Sciences | Cryotherapy | AVASTIN | EFFICACY | Humans | Infant | Laser Therapy [methods] | DIODE-LASER | Aptamers, Nucleotide [administration & dosage] | MEDICINE, GENERAL & INTERNAL | THERAPY | Angiogenesis Inhibitors [administration & dosage] | INFANTS | Bevacizumab [administration & dosage] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Retinopathy of Prematurity [drug therapy] | AGGRESSIVE POSTERIOR RETINOPATHY | LASER TREATMENT | Retinal Detachment [prevention & control] | Newborn | Cryotherapy [methods] | ZONE-I | INTRAVITREAL BEVACIZUMAB | RANIBIZUMAB | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Aptamers, Nucleotide - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Aptamers, Nucleotide - adverse effects | Ranibizumab - adverse effects | Angiogenesis Inhibitors - administration & dosage | Retinopathy of Prematurity - drug therapy | Laser Therapy - methods | Ranibizumab - administration & dosage | Cryotherapy - methods | Retinal Detachment - prevention & control | Angiogenesis Inhibitors - adverse effects | Infant, Newborn
Journal Article
Journal Article
Journal Article
Eye (London), ISSN 0950-222X, 2013, Volume 27, Issue 9, pp. 1090 - 1097
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 13, pp. 1193 - 1203
Journal Article
Retina (Philadelphia, Pa.), ISSN 0275-004X, 2017, Volume 37, Issue 10, pp. 1847 - 1858
Journal Article
JAMA ophthalmology, ISSN 2168-6165, 11/2017, Volume 136, Issue 1, pp. 29 - 38
Journal Article
Current Eye Research, ISSN 0271-3683, 2/2013, Volume 38, Issue 2, pp. 278 - 282
Journal Article
PloS one, ISSN 1932-6203, 2013, Volume 8, Issue 7, p. e67495
The long term in vivo biocompatibility is an essential feature for the design and development of sustained drug release carriers. In the recent intraocular... 
VITRO | DIBLOCK COPOLYMER | BEHAVIOR | MULTIDISCIPLINARY SCIENCES | MACULAR DEGENERATION | RELEASE | NEOVASCULARIZATION | TRIBLOCK | CYTOTOXICITY | RANIBIZUMAB | ENDOTHELIAL GROWTH-FACTOR | Polyamines - administration & dosage | Retina - drug effects | Laminin - toxicity | Proteoglycans - toxicity | Biocompatible Materials - chemistry | Drug Carriers - administration & dosage | Laminin - administration & dosage | Collagen - chemistry | Drug Carriers - toxicity | Polyamines - toxicity | Proteoglycans - chemistry | Biocompatible Materials - toxicity | Drug Carriers - chemistry | Hydrogels - administration & dosage | Polyesters - administration & dosage | Collagen - toxicity | Female | Hydrogels - toxicity | Poloxamer - administration & dosage | Poloxamer - chemistry | Rabbits | Polyamines - chemistry | Proteoglycans - administration & dosage | Polyesters - toxicity | Collagen - administration & dosage | Poloxamer - toxicity | Polyesters - chemistry | Animals | Laminin - chemistry | Biocompatible Materials - administration & dosage | Retina - pathology | Drug Combinations | Hydrogels - chemistry | Drugs | Drug delivery systems | Biological products | Vehicles | Cell culture | Diabetic retinopathy | Drug carriers | Hydrogels | Laboratories | Toxicity | Chemical engineering | Electrophysiology | Thermosensitive | Cytotoxicity | Drug delivery | Drug development | Phase transitions | Block copolymers | Polyethyloxazoline | Macular degeneration | Biomedical materials | Extracellular matrix | Biocompatibility | Vascular endothelial growth factor | Controlled release | Biodegradation | Tissue engineering | Therapeutic applications | Poloxamers | Gelation | Histology | Photography | Medicine | Stem cells | Sustained release | In vivo methods and tests | Media (culture) | Carriers
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 10011, pp. 2395 - 2403
Journal Article